fibrosis/protease

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to a composition and method for treating pancreatic enzyme insufficiency, particularly lipid malabsorbtion associated with cystic fibrosis. 2. Description of Related Art Various diseased states such as pancreatitis,

BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes, which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in common a catalytic triad consisting of Serine-195, Histidine-57 and Aspartic acid-102(chymotrypsin numbering system). Human

BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes, which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in common a catalytic triad consisting of Serine-195, Histidine-57 and Aspartic acid-102(chymotrypsin numbering system). Human

REFERENCE TO A SEQUENCE LISTING This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference. TECHNICAL FIELD The present invention relates to a protease having at least 90% identity to amino acids 1-188 of SEQ ID NO: 1, and

The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin.

The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes which include elastase, chymotrypsin, cathepsin G, trypsin and thrombin.

BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes, which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in common a catalytic triad consisting of Serine-195, Histidine-57 and Aspartic acid-102 (chymotrypsin numbering system). Human

The present invention relates to certain substituted oxadiazole nonpeptides, which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes, which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in

The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin.

The present invention relates to certain substituted oxadiazole nonpeptides, which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes, which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in

The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases. BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin.

BACKGROUND OF THE INVENTION The serine proteases are a class of enzymes which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin. These proteases have in common a catalytic triad consisting of Serine-195, Histidine-57 and Aspartic acid-102 (chymotrypsin numbering system). Human

BACKGROUND OF THE INVENTION Technical Field of the Invention The present invention relates in a first aspect to a monoclonal antibody which is specifically reactive with the C-terminal neo-epitope of PIIINP, and its use in a method of immunoassay for detecting and quantifying PIIINP. In a further

CROSS-REFERENCE TO RELATED APPLICATIONS The present application is the United States National Phase of PCT Application No. PCT/AU2012/000891, filed Jul. 27, 2012, which claims priority to PCT/AU2011/000959, filed Jul. 28, 2011, and to AU 2011904617, filed Nov. 7, 2011, the entire contents of each of

REFERENCE TO A SEQUENCE LISTING This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference. TECHNICAL FIELD The present invention relates to a lipase for use as a medicament, which lipase (a) has at least 50% identity to the